External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Thematic (Sector/Industry)

<ul><li>Pharmaceuticals: We expect pharmaceutical companies under our coverage to deliver a subdued yet positive performance in Q2FY27, with aggregate revenue rising 7.0% YoY and 3.6% QoQ to Rs 40,903 Cr.</li><li>However, EBITDA is estimated to decline 10% YoY but rise 6.3% QoQ to Rs 8,308 Cr, while adjusted PAT is likely to decline 19.6% YoY but moderately rise by 4.2% sequentially to Rs 4,331 Cr.</li><li>According to IQVIA data, chronic care segments such as cardiovascular and antidiabetic treatments are sustaining their outperformance against the broader Indian Pharmaceutical Market. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pharmaceuticals: We expect pharmaceutical companies under our coverage to deliver a subdued yet positive performance in Q2FY27, with aggregate revenue rising 7.0% YoY and 3.6% QoQ to Rs 40,903 Cr.However, EBITDA is estimated to decline 10% YoY but rise 6.3% QoQ to Rs 8,308 Cr, while adjusted PAT is likely to decline 19.6% YoY but moderately rise by 4.2% sequentially to Rs 4,331 Cr.According to IQVIA data, chronic care segments such as cardiovascular and antidiabetic treatments are sustaining their outperformance against the broader Indian Pharmaceutical Market. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pharma and Healthcare - Q2FY27E: Result Preview

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

Rainbow Children's Medicare / Equity Bottom-Up

<ul>
 <li>
<a href="https://smartkarma.com/entities/rainbow-children-s-medicare-limited">Rainbow Children's Medicare</a> is a leading pediatric and maternity healthcare provider in India, operating on a capital-efficient hub-and-spoke model that has driven strong historical growth and profitability.</li>
 <li>The company is in a significant expansion phase, aiming to add over 1,000 beds in the next 3-4 years, funded primarily through internal accruals, with a strategic focus on strengthening its presence in existing markets and entering new geographies like Delhi-NCR.</li>
 <li>While the company faces risks from seasonality and execution challenges with new hospitals, its specialized focus, strong brand equity, and diversification into women's healthcare position it well to capitalize on the growing Indian healthcare market.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
Rainbow Children's Medicare is a leading pediatric and maternity healthcare provider in India, operating on a capital-efficient hub-and-spoke model that has driven strong historical growth and profitability.
  The company is in a significant expansion phase, aiming to add over 1,000 beds in the next 3-4 years, funded primarily through internal accruals, with a strategic focus on strengthening its presence in existing markets and entering new geographies like Delhi-NCR.
  While the company faces risks from seasonality and execution challenges with new hospitals, its specialized focus, strong brand equity, and diversification into women's healthcare position it well to capitalize on the growing Indian healthcare market.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Rainbow Children's Medicare (RAINBOW IN) - Aug 2026

<ul><li>Muted Revenue Performance: Rainbow reported print below expectations. Revenue grew 33% YoY but remained flat QoQ. The quarter was impacted by seasonal softness and muted growth in mature assets at 1,550 beds. Newly acquired assets supported the top line, while the base business grew in single digits.</li><li>Stabilised Margins: The company reported an EBITDA margin of 28%, declining 282 bps QoQ and 71 bps YoY. EBITDA stood at Rs 135 Cr, up 30% YoY, while PAT came in at Rs 63 Cr, with lower growth than EBITDA at 16%. Despite seasonal headwinds and the gestation period of newly added capacity, margins remained stable and non-volatile.</li><li>ARPOB Driving Growth: Average Revenue Per Occupied Bed (ARPOB) stood at Rs 67,256, up 6.2% YoY and 7.7% QoQ in Q1FY27, reflecting continued improvement in case mix, pricing, and operational efficiency. Overall hospital occupancy declined to 41.2% from 45.3% in Q4FY26. IP discharges improved 28% YoY, while deliveries increased 23% YoY. Total operational bed count stood at 2,435, up 26% YoY.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Muted Revenue Performance: Rainbow reported print below expectations. Revenue grew 33% YoY but remained flat QoQ. The quarter was impacted by seasonal softness and muted growth in mature assets at 1,550 beds. Newly acquired assets supported the top line, while the base business grew in single digits.Stabilised Margins: The company reported an EBITDA margin of 28%, declining 282 bps QoQ and 71 bps YoY. EBITDA stood at Rs 135 Cr, up 30% YoY, while PAT came in at Rs 63 Cr, with lower growth than EBITDA at 16%. Despite seasonal headwinds and the gestation period of newly added capacity, margins remained stable and non-volatile.ARPOB Driving Growth: Average Revenue Per Occupied Bed (ARPOB) stood at Rs 67,256, up 6.2% YoY and 7.7% QoQ in Q1FY27, reflecting continued improvement in case mix, pricing, and operational efficiency. Overall hospital occupancy declined to 41.2% from 45.3% in Q4FY26. IP discharges improved 28% YoY, while deliveries increased 23% YoY. Total operational bed count stood at 2,435, up 26% YoY.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Rainbow Children's Medicare: Seasonality Leads to Softness

<ul><li>Rainbow Children’s Medicare is a leading Indian hospital chain specialising in paediatric, neonatal, perinatal, and women's healthcare.</li><li>By combining medical expertise, innovation, and standardised practices, the organisation consistently delivers high-quality patient outcomes.</li><li>It aims to ensure all mothers, fetuses, newborns, and children have access to high-standard tertiary care.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Rainbow Children’s Medicare is a leading Indian hospital chain specialising in paediatric, neonatal, perinatal, and women's healthcare.By combining medical expertise, innovation, and standardised practices, the organisation consistently delivers high-quality patient outcomes.It aims to ensure all mothers, fetuses, newborns, and children have access to high-standard tertiary care.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

PICK OF THE WEEK: Rainbow Children’s Medicare Ltd - 11th July, 2026

<ul><li>Muted Revenue Performance: Rainbow reported print below expectations. Revenue growing 12% YoY but remaining flat QoQ.</li><li>The quarter was impacted by seasonal softness and muted growth in mature assets.</li><li>The top line was supported by newly acquired assets, while the base business grew in single digits.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Muted Revenue Performance: Rainbow reported print below expectations. Revenue growing 12% YoY but remaining flat QoQ.The quarter was impacted by seasonal softness and muted growth in mature assets.The top line was supported by newly acquired assets, while the base business grew in single digits.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Rainbow Children’s Medicare Ltd - Seasonality Leads to Softness

India

Rainbow Children's Medicare Limited is a leading multi-specialty pediatric, obstetrics, and gynecology healthcare chain in India. The company provides a comprehensive suite of services including newborn and pediatric intensive care, multi-specialty pediatric services, and women's healthcare services such as normal and complex obstetric care, fetal medicine, and fertility treatments. Headquartered in Hyderabad, Telangana, the company was founded in 1999.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Rainbow Children's Medicare (RAINBOW IN)

Pharma and Healthcare - Q2FY27E: Result Preview

We expect pharmaceutical companies under our coverage to deliver a subdued yet positive performance in Q2FY27, with aggregate revenue rising 7.0%...

Axis Direct

Primer: Rainbow Children's Medicare (RAINBOW IN) - Aug 2026

Rainbow Children's Medicare is a leading pediatric and maternity healthcare provider in India, operating on a capital-efficient hub-and-spoke...

αSK Primers

Rainbow Children's Medicare: Seasonality Leads to Softness

We expect double-digit revenue growth with sustained ~30% EBITDA margins over the medium term, backed by disciplined execution and favourable...

Axis Direct

PICK OF THE WEEK: Rainbow Children’s Medicare Ltd - 11th July, 2026

Rainbow Children’s Medicare is a leading Indian hospital chain specialising in paediatric, neonatal, perinatal, and women's healthcare.

Axis Direct

Rainbow Children’s Medicare Ltd - Seasonality Leads to Softness

The quarter was impacted by seasonal softness and muted growth in mature assets.The top line was supported by newly acquired assets, while the base...

Axis Direct

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)